Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national blog main
national top stories
new york blog main
new york top stories
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
life sciences
affordable care act
biotech
clinical trials
fda
merck
nonalcoholic steatohepatitis
abeona therapeutics
cancer immunotherapy
deals
donald trump
johnson & johnson
pembrolizumab
regeneron pharmaceuticals
What
nash
6
×
roundup
6
×
bio
news
drug
american
based
best
biogen’s
companies
continue
crash
debate
disease
healthcare
industry
kind
people
pharmaceutical
policy
politicians
pressure
scalps
trump’s
u.s
according
aducanumab
akcea
alzheimer’s
amyloid
angst
approval
approved
bagged
billions
biogen
biopharmaceutical
biotech
brammer
cases
Language
unset
Current search:
xconomy.com
×
" new york top stories "
×
nash
×
roundup
×
@xconomy.com
5 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More